Clinical trials: HPV Infection
HPV Infection
An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen
The goal of this study is to explore and evaluate whether a 2-dose schedule of Gardasil 9 among young and mid-adult women 16-45 years of age is generally safe and immunogenic, with an antibody response that is not inferior to…
- Trial name
- NCT04206813
- Testing
- Gardasil 9 2 dose regimen, Gardasil 9 3 dose regimen, Gardasil 9 rescue dose
- Where
- United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Hpv
Effectiveness of HPV Vaccine Among Adolescents and Reproductive Women
To assess the effectiveness of HPV vaccine 2 doses or less to prevent HPV high risk infection among adolescents and adults. We conduct the test-negative control study including 12-45 women who interest to do a check-up pap smear.
- Trial name
- NCT06220747
- Where
- 2 sites in Thailand
- Volunteers
- 760 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Human Papillomavirus (HPV) Infection
Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in Children
This study will evaluate the safety and immune response of a single dose of a quadrivalent human papillomavirus (HPV) vaccine when given together with a tetanus-diphtheria (Td) vaccine in healthy children and adolescents aged 9…
- Trial name
- NCT07824310
- Testing
- Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine, Tetanus-Diphtheria booster
- Where
- Indonesia
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
HPV Infection, Vaccine Preventable Disease
Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania
Add-Vacc is an unblinded cluster-randomised trial (CRT) with two arms: (i) the national HPV vaccination programme (girls aged ~14 years, control arm) and (ii) the national programme plus single-dose male HPV vaccination given to…
- Trial name
- Add-Vacc (NCT04953130)
- Testing
- Gardasil® HPV vaccine
- Where
- Tanzania
- Volunteers
- 10,400 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
HIV, Chlamydia
National Rapid TLC: Testing and Linkage to Care
The goal of this cross-sectional study is to learn if the GeneXpert system is a practical system for HIV and STBBI testing in community-based organizations and health clinics.
- Conditions
- HIV, Chlamydia, Gonorrhea, HCV
- Trial name
- NCT07730801
- Testing
- Xpert® HIV-1 Qual XC
- Where
- 2 sites in Canada
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
HPV Infection
Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years
This study aims to assess the immunogenicity and safety of a sequential 2vhpv to 9vhpv immunization schedule in girls aged 9-14 years
- Trial name
- NCT07281677
- Testing
- bivalent HPV vaccine, 9-valent HPV vaccine
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
Hpv
Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination
Each year in the U.S., ≥20,000 women and 14,000 men are affected by HPV-related cancers, including cervical and oropharyngeal cancer. However, in 2020, only 59% of U.S.
- Trial name
- NCT06380114
- Testing
- Communication, Standing Orders
- Where
- United States
- Volunteers
- 16,000 people, healthy volunteers welcome
- Sponsor
- University of Rochester
HPV Infection, Vaccine-Preventable Diseases
Game-Based Intervention to Promote HPV Vaccination
This study will examine the feasibility and acceptability of an innovative game-based intervention designed for families of youth aged 11-14 to promote HPV vaccination; will explore changes in key outcomes and related measures…
- Trial name
- NCT06162676
- Testing
- HPV game
- Where
- United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Michigan State University
Human Papillomavirus (HPV) Vaccine, Human Papillomavirus (HPV) Vaccines
Strengthening HPV Vaccination and Adolescent Health Research Program in Nigeria (SHARP)
The goal of this clinical trial is to learn whether adding adolescent health services to routine government health programs can increase Human Papillomavirus (HPV) vaccination coverage among 9-year-old girls and improve use of…
- Conditions
- Human Papillomavirus (HPV) Vaccine, Human Papillomavirus (HPV) Vaccines, Human Papillomavirus (HPV) Infections, Adolescent Health Services
- Trial name
- SHARP (NCT07200414)
- Testing
- Integrated Adolescent Health Package, Routine Government Health Services
- Where
- Nigeria
- Volunteers
- 12,654 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Cancer , Healthy, HPV - Anogenital Human Papilloma Virus Infection
The Effect of the Health Belief Model-Based Education Given to Mothers of Children Aged 9-15 on HPV Knowledge Level and Child Vaccination
This study aims to examine the effects of education provided to mothers of children aged 9-15 within the framework of the Health Belief Model on mothers' knowledge, attitudes, and behaviors about Human Papillomavirus (HPV), and…
- Conditions
- Cancer , Healthy, HPV - Anogenital Human Papilloma Virus Infection, Health Belief Model
- Trial name
- NCT07450703
- Testing
- HEALTH BELİEF MODEL
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Gaziantep
Human Papillomavirus (HPV) Infection, HPV (Human Papillomavirus)-Associated Carcinoma
Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging
This vaccine was jointly developed by Chengdu Institute of Biological Products Co., Ltd. and National Vaccine and Serum Institute, China, is co-sponsoring this clinical trial.
- Trial name
- NCT06632912
- Testing
- 2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha), 3 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
- Where
- 3 sites in China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
HPV Infection, HPV-Related Carcinoma
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.
- Conditions
- HPV Infection, HPV-Related Carcinoma, HPV-Related Intraepithelial Neoplasia, Genital Wart
- Trial name
- NCT06756269
- Testing
- Medium dose for 15-HPV vaccine, High dose for 15-HPV vaccine, 9-HPV vaccine
- Where
- China
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
HPV, HIV Infections
Gut and Vaginal Microbiota Profile Study for HIV Women
Women Living with HIV Infection （WLHIV）are intended to acquire HPV infection which usually contributes to variable cervical lesions.
- Conditions
- HPV, HIV Infections, Vaginal Microbiota
- Trial name
- NCT05996016
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
HPV Infection, Cervical Disease
Impact of HPV Vaccination on HPV Infection and Cervical Related Disease Burden in Real-World Settings (HPV-RWS)
Take AS04 adjuvanted HPV16/18 vaccine as an example to evaluate the impact of HPV vaccination on HPV infection and related disease burden in the real world based on prospective cohort and Yinzhou Regional Health Information…
- Trial name
- HPV-RWS (NCT05341284)
- Testing
- Questionnaire Survey and Cervical Cancer Screening
- Volunteers
- healthy volunteers welcome
- Sponsor
- Peking University
HPV-Related Carcinoma, HPV Infection
Determining the Frequency of Occurrence and Defining the Most Appropriate Screening Test for Anal Intraepithelial Neoplasia (AIN) in Patients With Human Papillomavirus (HPV) Related Gynecological Diseases.
The primary aim of the study is to determine the total risk of AIN in group of HPV-RGD survivors and additionally to establish an exact risk for each of HPV-related gynecological precancers/cancers.
- Trial name
- NCT06574087
- Testing
- hrHPV test and cytology
- Where
- Poland
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- PCK Marine Hospital in Gdynia
HPV Infection
Global Burden Estimation of Human Papillomavirus (GLOBE-HPV)
This study is a multi-country and multi-site project to estimate the point-prevalence of high-risk (HR) HPV genotype infections among representative samples of girls and women aged 9-50 years, and among specific sub-populations…
- Trial name
- HPV (NCT06129253)
- Testing
- Urine Sample Collection, Self-collected Vaginal Swab, Blood Samples
- Where
- 8 sites in Bangladesh, Democratic Republic of the Congo and 6 more
- Volunteers
- 29,750 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Human Papilloma Virus (HPV), Cervical Carcinoma
Transmission of Oncogenic HPV Infection Among Families
The goal of the Transmission of Oncogenic HPV Infection Among Families (TREVINO) study is to improve understanding of how high-risk human papillomavirus (HPV) infections are transmitted within families.
- Conditions
- Human Papilloma Virus (HPV), Cervical Carcinoma, Oropharyngeal Carcinoma, Transmission Vertical
- Trial name
- TREVINO (NCT07036211)
- Where
- 2 sites in Finland
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Tampere University Hospital
HPV Infections
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)
This study is designed to determine the tolerability and immunogenicity of a 3-dose regimen of Gardasil administered to healthy married females between 16 and 23 years of age, in India.
- Trial name
- NCT00733122
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Safety Issues, HPV Infection
BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects
This is a follow-up study for patients treated with FluBHPVE6E7 in previous interventional studies.
- Trial name
- NCT04528407
- Testing
- Observation without intervention
- Where
- Austria
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- BlueSky Immunotherapies GmbH